Follow the 엔케이젠바이오텍코리아 stock price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares trade on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 엔케이젠바이오텍코리아 has published 51 public disclosures. The latest transaction was filed on 10 July 2025 (Purchase). Among the most active insiders: 박근호. The full history is openly available.
51
Insider Decl.
n/a
Thresholds
n/a
34 ops.
Buy Volume
n/a
4 ops.
Sell Volume
5Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
NK Gen Biotech Korea is a company in the health and pharmaceutical sector, listed on the XKRX market. It specializes in the development of biopharmaceutical solutions.